Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
- Autores
- Srinivasan, Venkatramanujam; Brzezinski, Amnon; Spence Warren, D.; Pandi Perumal, Seithikurippu R.; Hardeland, Rüdiger; Brown, Gregory M.; Cardinali, Daniel Pedro
- Año de publicación
- 2010
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Insomnia often precedes the appearance of mood changes. While the presence of disturbed sleep prior to the onset of depressed mood is useful prognostically, the ultimate co-occurrence of these symptoms can pose a considerable challenge for pharmaceutical therapy. Most currently used antidepressants (tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin receptor-2 antagonist/serotonin reuptake inhibitors, selective serotonin reuptake inhibitors) are effective antidepressants but they have the disadvantage that often aggravate sleep disturbances. An ideal antidepressant should address both problems: such an antidepressant should exert a rapid onset of action both on depressive symptomatology as well on sleep problems. The recently introduced novel antidepressant agomelatine has melatonergic agonist and 5-HT2C antagonistic properties, and has been found effective in improving both depressive mood and sleep disturbances. Its mechanism of action differs from the currently used antidepressants. It thus represents a possible first line drug for treatment of mood disorders such as major depressive disorder, bipolar disorder and seasonal affective disorder. This review summarises what is known about the clinical efficacy and mechanism of action of agomelatine and compares these findings with those of currently available antidepressants.
Fil: Srinivasan, Venkatramanujam. No especifíca;
Fil: Brzezinski, Amnon. No especifíca;
Fil: Spence Warren, D.. No especifíca;
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;
Fil: Hardeland, Rüdiger. No especifíca;
Fil: Brown, Gregory M.. No especifíca;
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
INSOMNIA
SLEEP
MOOD DISORDERS
ANTIDEPRESSANTS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/190921
Ver los metadatos del registro completo
id |
CONICETDig_b63a35b5a179d5f88e5e56b3ba22a89a |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/190921 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatmentSrinivasan, VenkatramanujamBrzezinski, AmnonSpence Warren, D.Pandi Perumal, Seithikurippu R.Hardeland, RüdigerBrown, Gregory M.Cardinali, Daniel PedroINSOMNIASLEEPMOOD DISORDERSANTIDEPRESSANTShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Insomnia often precedes the appearance of mood changes. While the presence of disturbed sleep prior to the onset of depressed mood is useful prognostically, the ultimate co-occurrence of these symptoms can pose a considerable challenge for pharmaceutical therapy. Most currently used antidepressants (tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin receptor-2 antagonist/serotonin reuptake inhibitors, selective serotonin reuptake inhibitors) are effective antidepressants but they have the disadvantage that often aggravate sleep disturbances. An ideal antidepressant should address both problems: such an antidepressant should exert a rapid onset of action both on depressive symptomatology as well on sleep problems. The recently introduced novel antidepressant agomelatine has melatonergic agonist and 5-HT2C antagonistic properties, and has been found effective in improving both depressive mood and sleep disturbances. Its mechanism of action differs from the currently used antidepressants. It thus represents a possible first line drug for treatment of mood disorders such as major depressive disorder, bipolar disorder and seasonal affective disorder. This review summarises what is known about the clinical efficacy and mechanism of action of agomelatine and compares these findings with those of currently available antidepressants.Fil: Srinivasan, Venkatramanujam. No especifíca;Fil: Brzezinski, Amnon. No especifíca;Fil: Spence Warren, D.. No especifíca;Fil: Pandi Perumal, Seithikurippu R.. No especifíca;Fil: Hardeland, Rüdiger. No especifíca;Fil: Brown, Gregory M.. No especifíca;Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFoundation for Psychiatric Research in Finland2010-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/190921Srinivasan, Venkatramanujam; Brzezinski, Amnon; Spence Warren, D. ; Pandi Perumal, Seithikurippu R.; Hardeland, Rüdiger; et al.; Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment; Foundation for Psychiatric Research in Finland; Psychiatria Fennica; 41; 9-2010; 168-1870079-7227CONICET DigitalCONICETenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:25:14Zoai:ri.conicet.gov.ar:11336/190921instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:25:15.101CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment |
title |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment |
spellingShingle |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment Srinivasan, Venkatramanujam INSOMNIA SLEEP MOOD DISORDERS ANTIDEPRESSANTS |
title_short |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment |
title_full |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment |
title_fullStr |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment |
title_full_unstemmed |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment |
title_sort |
Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment |
dc.creator.none.fl_str_mv |
Srinivasan, Venkatramanujam Brzezinski, Amnon Spence Warren, D. Pandi Perumal, Seithikurippu R. Hardeland, Rüdiger Brown, Gregory M. Cardinali, Daniel Pedro |
author |
Srinivasan, Venkatramanujam |
author_facet |
Srinivasan, Venkatramanujam Brzezinski, Amnon Spence Warren, D. Pandi Perumal, Seithikurippu R. Hardeland, Rüdiger Brown, Gregory M. Cardinali, Daniel Pedro |
author_role |
author |
author2 |
Brzezinski, Amnon Spence Warren, D. Pandi Perumal, Seithikurippu R. Hardeland, Rüdiger Brown, Gregory M. Cardinali, Daniel Pedro |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
INSOMNIA SLEEP MOOD DISORDERS ANTIDEPRESSANTS |
topic |
INSOMNIA SLEEP MOOD DISORDERS ANTIDEPRESSANTS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Insomnia often precedes the appearance of mood changes. While the presence of disturbed sleep prior to the onset of depressed mood is useful prognostically, the ultimate co-occurrence of these symptoms can pose a considerable challenge for pharmaceutical therapy. Most currently used antidepressants (tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin receptor-2 antagonist/serotonin reuptake inhibitors, selective serotonin reuptake inhibitors) are effective antidepressants but they have the disadvantage that often aggravate sleep disturbances. An ideal antidepressant should address both problems: such an antidepressant should exert a rapid onset of action both on depressive symptomatology as well on sleep problems. The recently introduced novel antidepressant agomelatine has melatonergic agonist and 5-HT2C antagonistic properties, and has been found effective in improving both depressive mood and sleep disturbances. Its mechanism of action differs from the currently used antidepressants. It thus represents a possible first line drug for treatment of mood disorders such as major depressive disorder, bipolar disorder and seasonal affective disorder. This review summarises what is known about the clinical efficacy and mechanism of action of agomelatine and compares these findings with those of currently available antidepressants. Fil: Srinivasan, Venkatramanujam. No especifíca; Fil: Brzezinski, Amnon. No especifíca; Fil: Spence Warren, D.. No especifíca; Fil: Pandi Perumal, Seithikurippu R.. No especifíca; Fil: Hardeland, Rüdiger. No especifíca; Fil: Brown, Gregory M.. No especifíca; Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
description |
Insomnia often precedes the appearance of mood changes. While the presence of disturbed sleep prior to the onset of depressed mood is useful prognostically, the ultimate co-occurrence of these symptoms can pose a considerable challenge for pharmaceutical therapy. Most currently used antidepressants (tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin receptor-2 antagonist/serotonin reuptake inhibitors, selective serotonin reuptake inhibitors) are effective antidepressants but they have the disadvantage that often aggravate sleep disturbances. An ideal antidepressant should address both problems: such an antidepressant should exert a rapid onset of action both on depressive symptomatology as well on sleep problems. The recently introduced novel antidepressant agomelatine has melatonergic agonist and 5-HT2C antagonistic properties, and has been found effective in improving both depressive mood and sleep disturbances. Its mechanism of action differs from the currently used antidepressants. It thus represents a possible first line drug for treatment of mood disorders such as major depressive disorder, bipolar disorder and seasonal affective disorder. This review summarises what is known about the clinical efficacy and mechanism of action of agomelatine and compares these findings with those of currently available antidepressants. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/190921 Srinivasan, Venkatramanujam; Brzezinski, Amnon; Spence Warren, D. ; Pandi Perumal, Seithikurippu R.; Hardeland, Rüdiger; et al.; Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment; Foundation for Psychiatric Research in Finland; Psychiatria Fennica; 41; 9-2010; 168-187 0079-7227 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/190921 |
identifier_str_mv |
Srinivasan, Venkatramanujam; Brzezinski, Amnon; Spence Warren, D. ; Pandi Perumal, Seithikurippu R.; Hardeland, Rüdiger; et al.; Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment; Foundation for Psychiatric Research in Finland; Psychiatria Fennica; 41; 9-2010; 168-187 0079-7227 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Foundation for Psychiatric Research in Finland |
publisher.none.fl_str_mv |
Foundation for Psychiatric Research in Finland |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842981400374935552 |
score |
12.48226 |